Call Calendar

ERasmus+

Horizon europe - pillars 2 & 3

jOINT CALL CALENDAR

ROADMAP 2021-2022

iNTERREG EUROPE

oTHER ACTIONS

eUROPEAN RESEARCH COUNCIL

Small partnerships

ASOCIACIONES DE COOPERACIÓN El objetivo principal de las asociaciones de cooperación es permitir que las organizaciones incrementen la calidad y pertinencia de sus actividades, amplíen y refuercen sus redes de organizaciones asociadas e incrementen su capacidad para operar de manera conjunta a nivel transnacional, impulsando la internacionalización de sus actividades, también intercambiando o desarrollando prácticas y métodos nuevos, así como poniendo en común y confrontando ideas. Tienen por objeto apoyar el desarrollo, la transferencia o la implementación de prácticas innovadoras, así como la ejecución de iniciativas conjuntas que fomenten la cooperación, el aprendizaje entre iguales y el intercambio de experiencias a escala europea. Los resultados han de ser reutilizables, transferibles, ampliables y, a ser posible, incorporar una fuerte dimensión transdisciplinar. Se espera que los proyectos seleccionados compartan los resultados de sus actividades a nivel local, regional, nacional y transnacional. Las asociaciones de cooperación se asientan sobre las prioridades y los marcos estratégicos de cada sector Erasmus+, tanto a nivel europeo como nacional, y, al mismo tiempo, procuran generar incentivos para la cooperación horizontal y entre sectores en ámbitos temáticos. OBJETIVOS DE LA ACCIÓN La finalidad de las asociaciones de cooperación es:  mejorar la calidad del trabajo, las actividades y las prácticas de las organizaciones e instituciones implicadas, abriéndose a nuevos agentes que normalmente no están incluidos en un sector;  desarrollar la capacidad de las organizaciones para trabajar a nivel transnacional y entre sectores;  atender a prioridades y necesidades comunes en los ámbitos de la educación, la formación, la juventud y el deporte;  propiciar la transformación y el cambio (a nivel individual, sectorial o de organización), dando lugar a mejoras y nuevos enfoques de manera proporcional al contexto de cada organización. Despite advances in immunotherapies, obstacles and challenges, including limited response rates, the inability to predict clinical efficacy, and potential side effects such as autoimmune reactions or cytokine release syndromes, remain and hinder further applications of immunotherapies in clinics. Thus, a deeper understanding of the TME, able to dissect distinct classes and subclasses of it, is essential for deciphering new mechanisms of immunotherapies, defining new predictive biomarkers, and identifying novel therapeutic targets. In the context of translational research, this topic at the intersection of laboratory and clinical research in immuno-oncology will comprise two general aims: Aim 1: Identification and validation of TME subclasses and their contribution to the resistance mechanisms: Translational research using tumour samples collected from retrospective and/or prospective cohorts of patients. Aim 2: Targeting TME to improve efficacy of immunotherapy in human patients.

Cooperation partnership 2

ASOCIACIONES DE COOPERACIÓN El objetivo principal de las asociaciones de cooperación es permitir que las organizaciones incrementen la calidad y pertinencia de sus actividades, amplíen y refuercen sus redes de organizaciones asociadas e incrementen su capacidad para operar de manera conjunta a nivel transnacional, impulsando la internacionalización de sus actividades, también intercambiando o desarrollando prácticas y métodos nuevos, así como poniendo en común y confrontando ideas. Tienen por objeto apoyar el desarrollo, la transferencia o la implementación de prácticas innovadoras, así como la ejecución de iniciativas conjuntas que fomenten la cooperación, el aprendizaje entre iguales y el intercambio de experiencias a escala europea. Los resultados han de ser reutilizables, transferibles, ampliables y, a ser posible, incorporar una fuerte dimensión transdisciplinar. Se espera que los proyectos seleccionados compartan los resultados de sus actividades a nivel local, regional, nacional y transnacional. Las asociaciones de cooperación se asientan sobre las prioridades y los marcos estratégicos de cada sector Erasmus+, tanto a nivel europeo como nacional, y, al mismo tiempo, procuran generar incentivos para la cooperación horizontal y entre sectores en ámbitos temáticos. OBJETIVOS DE LA ACCIÓN La finalidad de las asociaciones de cooperación es:  mejorar la calidad del trabajo, las actividades y las prácticas de las organizaciones e instituciones implicadas, abriéndose a nuevos agentes que normalmente no están incluidos en un sector;  desarrollar la capacidad de las organizaciones para trabajar a nivel transnacional y entre sectores;  atender a prioridades y necesidades comunes en los ámbitos de la educación, la formación, la juventud y el deporte;  propiciar la transformación y el cambio (a nivel individual, sectorial o de organización), dando lugar a mejoras y nuevos enfoques de manera proporcional al contexto de cada organización.

Website

Contact

Partnering IDIVAL

2021-2022

ERASMUS+ Key Actions 2 & 3

Cooperation partnerships 1

ASOCIACIONES DE COOPERACIÓN El objetivo principal de las asociaciones de cooperación es permitir que las organizaciones incrementen la calidad y pertinencia de sus actividades, amplíen y refuercen sus redes de organizaciones asociadas e incrementen su capacidad para operar de manera conjunta a nivel transnacional, impulsando la internacionalización de sus actividades, también intercambiando o desarrollando prácticas y métodos nuevos, así como poniendo en común y confrontando ideas. Tienen por objeto apoyar el desarrollo, la transferencia o la implementación de prácticas innovadoras, así como la ejecución de iniciativas conjuntas que fomenten la cooperación, el aprendizaje entre iguales y el intercambio de experiencias a escala europea. Los resultados han de ser reutilizables, transferibles, ampliables y, a ser posible, incorporar una fuerte dimensión transdisciplinar. Se espera que los proyectos seleccionados compartan los resultados de sus actividades a nivel local, regional, nacional y transnacional. Las asociaciones de cooperación se asientan sobre las prioridades y los marcos estratégicos de cada sector Erasmus+, tanto a nivel europeo como nacional, y, al mismo tiempo, procuran generar incentivos para la cooperación horizontal y entre sectores en ámbitos temáticos. OBJETIVOS DE LA ACCIÓN La finalidad de las asociaciones de cooperación es:  mejorar la calidad del trabajo, las actividades y las prácticas de las organizaciones e instituciones implicadas, abriéndose a nuevos agentes que normalmente no están incluidos en un sector;  desarrollar la capacidad de las organizaciones para trabajar a nivel transnacional y entre sectores;  atender a prioridades y necesidades comunes en los ámbitos de la educación, la formación, la juventud y el deporte;  propiciar la transformación y el cambio (a nivel individual, sectorial o de organización), dando lugar a mejoras y nuevos enfoques de manera proporcional al contexto de cada organización.

Evaluation period

Proposal submission

ENE

FEB

MAR

ABR

MAY

JUN

JUL

AGO

SEP

OCT

NOV

DIC

Jean Monnet

ACCIONES JEAN MONNET EN EL ÁMBITO DE LA EDUCACIÓN SUPERIOR La acción Jean Monnet en el terreno de la educación superior apoya la enseñanza y la investigación en el ámbito de los estudios sobre la Unión Europea en todo el mundo. Por «estudios sobre la Unión Europea» se entiende el estudio de Europa en su totalidad, con especial hincapié en la dimensión de la UE, desde una perspectiva interna, pero también mundial. El alcance de los estudios sobre la Unión Europea puede ser variable, siempre y cuando se explore el enfoque de la UE. Estos estudios deben promover la ciudadanía europea activa y los valores europeos y tratar el papel de la UE en un mundo globalizado, mejorando el conocimiento de la Unión y facilitando el compromiso futuro y el diálogo entre personas. La acción Jean Monnet también pretende servir como vector de diplomacia pública hacia terceros países, fomentando los valores de la UE y mejorando la visibilidad de lo que representa y lo que pretende conseguir la Unión Europea. A continuación, se describen los objetivos y los criterios que deben cumplirse para solicitar una acción sobre enseñanza e investigación. ENSEÑANZA E INVESTIGACIÓN OBJETIVOS DE LA ACCIÓN Las acciones Jean Monnet de enseñanza e investigación:  promoverán la excelencia en la enseñanza y la investigación en el ámbito de los estudios sobre la Unión Europea en todo el mundo;  impulsarán el diálogo entre el mundo académico y la sociedad, incluidos los responsables de la formulación de políticas a nivel local y estatal, los funcionarios públicos, los agentes de la sociedad civil, los representantes de los diferentes niveles de educación y de los medios de comunicación;  generarán conocimientos e ideas que apoyen la formulación de políticas de la UE y refuercen el papel de la UE en Europa y en un mundo globalizado;  llegarán a un público más amplio y difundirán el conocimiento sobre la UE a la sociedad en general (más allá del mundo académico y el público especializado), acercando la UE al público en general. La acción pretende servir asimismo como vector de diplomacia pública hacia países asociados, fomentando los valores de la UE y mejorando la visibilidad de lo que realmente representa y lo que pretende conseguir la Unión Europea.

Questions?

IDIVAL is the Health Research Institute of Cantabria, was created as a place for biomedical research, knowledge generation and socioeconomic tractor for the region as a result of the relationship that has been maintained over the years between the Marqués de Valdecilla University Hospital (HUMV) and the University of Cantabria (UC). Since its constitution in 2010, on March 2015, IDIVAL it is an accredited institution by the Health Institute Carlos III (ISCIII), and re accredited on June 2020 for a 5 years period, meaning that the work performed at IDIVAL meets the highest standards of quality. In fact, MVUH is ranked 59 of Health Institutions in SCImago Institutions Rankings (SIR) -Q1 Societal rank- in 2021 ranking and 319 worldwide (SIR). UC is ranked 3rd in Spain in productivity – sum of research, teaching and innovation (U-Ranking, BBVA Foundation & Ivie, 2020). The close collaboration between IDIVAL, UC, MVUH and the Health System, is allowing IDIVAL to foster basic-clinical collaborations and a fast-growing and excellent research activity, specifically oriented to generate new knowledge helping to solve the medical problems of the population. The Institution is made up of more than 750 people (workers, researchers and administrative staff). The scientific structure of IDIVAL includes 32 research groups distributed according to three categories (22 consolidated groups, 6 associated groups and 5 emerging groups), that focus their activity on six areas: cancer; neurosciences; transplantation; infection and immunity; metabolism, aging and lifestyle habits; and transversal research. IDIVAL has acquired an international reputation due to the the excellence of its standards of biomedical research, with a cumulative scientific production of more than 2,500 papers published, exceeding 7,000 citations, with an average of 8.4 citations per paper and an H-index of 58. Works published by researchers of the Institute in 2020 have reached 162,000 cumulative citations in the international literature. The 2017-2021 research plan approved by the institution is in line with Horizon Europe and the regional plan RIS3 for strategic development. IDIVAL is also a highly competitive research institute in terms of research funding. In 2019, IDIVAL attracted more than 8.5 M€ to fund its R&D activities, from which 2.3 M€ (27.8%) in competitive calls and 2.2 M€ from Cantabria Government (26.3%). The cumulative amount of research funding between 2015 and 2019 was more than 35.75 M€ (69.3% from competitive calls). Considering EU Projects, IDIVAL has experience in international research projects and programmes, participating in projects funded by the Seventh Framework Program (FP7, 2017-2013) and by the Horizon 2020 calls. During the last period of H2020 (2014-2020), IDIVAL has obtained funding for the TIMELY project (A patient-centered early risk prediction, prevention, and intervention platform to support the continuum of care in coronary artery disease (CAD) using eHealth and artificial intelligence), first of its type in our institution. In 2018 obtained one Interreg Sudoe grant as a Coordinator, called TichroN - Use of ICTs as a tool to improve the comprehensive care of children with chronic illnesses, and in 2019 its first Interreg Europe grant INTENCIVE - INnovation and Technology ENhancing Customer OrIented Health SerVicEs. In 2019, IDIVAL obtained its first MSCA Grant - HELICAL. Moreover in 2019-2020 it has obtained three grants of an IMI2 project: EDHEN - European Health Data Evidence Network + additional call for COVID-19 and PRECISEADS - Molecular reclassification to find clinically useful biomarkers for systemic autoimmune diseases. Regarding Erasmus+ calls, IDIVAL has an extensive experience, two of the last ongoing projects under this umbrella are ALADDIN - Development of a Specific Training on Additive Manufacturing Technologies for Hospitals and PSYCH UP - Improving support for people affected by psychological disorders during their training path. Concerning the Third EU Health Programme IDIVAL has obtained funding from two Joint Actions (JADECARE and Chrodis+). Finally, IDIVAL is part of different European Infraestructures as EATRIS and ECRIN, and has received the recognition as a Reference Site by the European Innovation Partnership. The European Commission has also recognized the institution with the “HR Excellence in Research Award”, showing its commitment to improve its Human Resources policies in line with the European Charter for Researchers and the Code of Conduct of the Recruitment of Researchers (available information on our HRS4R website. Finally IDIVAL has a strong track record in assisting international consortia in proposal preparation, contract negotiation, project implementation and communication, IDIVAL’s European Projects Office personnel offers professional support along the whole life cycle of an EU project. The Transfer Technology & Valorization and Innovation Offices manage IPRs and licensing matters arising from projects. Last, the Office for Transfer of Research Results assists in developing and exploitation of business strategies, as well as in identifying results with a potential to be translated into products for the benefit of the society. For more information please visit our website.

Key Action 2 Cooperation partnerships in the fields of education, training and youth, except for those submitted by European NGO's Deadline 20/05/2021 12:00 CET

Not published

Not published

Key Action 2 Cooperation partnerships in the fields of sport. Deadline 20/05/2021 17:00 CET

Not published

Not published

Key Action 2 Cooperation partnerships in the field of education and training and youth. Deadline 20/05/2021 12:00 CET

Key Action 2 Cooperation partnerships in the field of education and training and youth. Deadline 03/11/2021 12:00 CET

Not published

Key Action 3 Jean Monnet Actions and Networks Deadline 02/06/2021 17:00 CET

Website

Contact

Partnering IDIVAL

2021

Horizon Europe -Pillar 2 & 3

ENE

FEB

MAR

ABR

MAY

JUN

JUL

AGO

SEP

OCT

NOV

DIC

Estimated submission

3. To takle and reduce diseases

Destination 3. Tackling diseases & reducing disease burden

• HORIZON-HLTH-DISEASE-2021-04-01 Comparative effectiveness research for healthcare interventions in areas of high public health need
• HORIZON-HLTH-DISEASE-2021-04-02 Building a European innovation platform for the repurposing of medicinal products
• HORIZON-HLTH-DISEASE-2021-04-03 Clinical development of health technologies relevant in sub-Saharan Africa
• HORIZON-HLTH-DISEASE-2021-04-04 Advancing innovative Artificial Intelligence (AI)-based solutions for treatment
• HORIZON-HLTH-DISEASE-2021-04-05 One Health AMR
• HORIZON-HLTH-DISEASE-2021-04-06 EU Wide Clinical Trials Network - public health emergencies

2. Health promotion

Destination 2. Living & working in a health-promoting environment Call Enviromental and Health

• RIA: HORIZON-HLTH-ENVHLTH-2021-02-01: Health risk related to exposure to electromagnetic fields
• RIA: HORIZON-HLTH-ENVHLTH-2021-02-02: Indoor air quality and health

1. Staying healthy

Destination 1. Staying healthy in a rapidly changing society

• RIA: HORIZON-HLTH-STAYHLTH-2021-01-02: Towards a molecular and neurobiologicalunderstanding of mental health and mental illnessfor the benefit of citizens and patients
• CSA: HORIZON-HLTH-2021-STAYHLTH-01-03: Supporting digital empowerment and healthliteracy – Healthy citizens 2.0
• CSA: HORIZON-HLTH-2021-STAYHLTH-01-04: A roadmap for personalised prevention
• CSA: HORIZON-HLTH-2021-STAYHLTH-01-05: Mobilising the network of National Contact Points in the Health Cluster

6. Health industry

Destination 6. Maintaining an innovative, sustainable & globally competitive health industry

• HORIZON-HLTH-IND-2021-07-01 Green pharmaceuticals
• HORIZON-HLTH-IND-2021-07-02 New payment models for cost-effective and affordable health innovations/new models of pricing
• HORIZON-HLTH-IND-2021-07-03 Uptake of Technical specifications for “Quality and Reliability of Health and Wellness Apps” – promoting a trusted 'mhealth label' in Europe

5. New digital solutions

Destination 5. Unlocking the full potential of new tools, technologies and digital solutions for a healthy society

• HORIZON-HLTH-TOOL-2021-06 Smart medical devices and their surgical implantation for use in resource-constrained settings
• HORIZON-HLTH-TOOL-2021-06-02 Next generation advanced therapies to treat prevalent and high burden diseases with unmet needs
• HORIZON-HLTH-TOOL-2021-06-03 Innovative tools for use and re-use of health data (in particular electronic health records and/or patient registries)

4. Innovative Healthcare

Destination 4. Ensuring access to innovative, sustainable & high-quality Healthcare

• HORIZON-HLTH-CARE-2021-05-01 Enhancing quality of care and patient safety
• HORIZON-HLTH-CARE-2021-05-02 Data-driven decision-support tools for better health and care delivery and policy-making
• HORIZON-HLTH-CARE-2021-05-03 Personalised medicine and infectious diseases: understanding the individual host response to viruses (e.g., SARS-CoV-2)
• HORIZON-HLTH-CARE-2021-05-04 Health and Care procurement innovation network

EIC Path. Challenge

Targeting specific strategic priorities with early stage development of a radically new technology and high-risk/high-gain science-towards-technology breakthrough research.

EIC Path. Open

HEALTH

Pillar 2

Pillar 3

Proposal submission

Questions?

IDIVAL is the Health Research Institute of Cantabria, was created as a place for biomedical research, knowledge generation and socioeconomic tractor for the region as a result of the relationship that has been maintained over the years between the Marqués de Valdecilla University Hospital (HUMV) and the University of Cantabria (UC). Since its constitution in 2010, on March 2015, IDIVAL it is an accredited institution by the Health Institute Carlos III (ISCIII), and re accredited on June 2020 for a 5 years period, meaning that the work performed at IDIVAL meets the highest standards of quality. In fact, MVUH is ranked 59 of Health Institutions in SCImago Institutions Rankings (SIR) -Q1 Societal rank- in 2021 ranking and 319 worldwide (SIR). UC is ranked 3rd in Spain in productivity – sum of research, teaching and innovation (U-Ranking, BBVA Foundation & Ivie, 2020). The close collaboration between IDIVAL, UC, MVUH and the Health System, is allowing IDIVAL to foster basic-clinical collaborations and a fast-growing and excellent research activity, specifically oriented to generate new knowledge helping to solve the medical problems of the population. The Institution is made up of more than 750 people (workers, researchers and administrative staff). The scientific structure of IDIVAL includes 32 research groups distributed according to three categories (22 consolidated groups, 6 associated groups and 5 emerging groups), that focus their activity on six areas: cancer; neurosciences; transplantation; infection and immunity; metabolism, aging and lifestyle habits; and transversal research. IDIVAL has acquired an international reputation due to the the excellence of its standards of biomedical research, with a cumulative scientific production of more than 2,500 papers published, exceeding 7,000 citations, with an average of 8.4 citations per paper and an H-index of 58. Works published by researchers of the Institute in 2020 have reached 162,000 cumulative citations in the international literature. The 2017-2021 research plan approved by the institution is in line with Horizon Europe and the regional plan RIS3 for strategic development. IDIVAL is also a highly competitive research institute in terms of research funding. In 2019, IDIVAL attracted more than 8.5 M€ to fund its R&D activities, from which 2.3 M€ (27.8%) in competitive calls and 2.2 M€ from Cantabria Government (26.3%). The cumulative amount of research funding between 2015 and 2019 was more than 35.75 M€ (69.3% from competitive calls). Considering EU Projects, IDIVAL has experience in international research projects and programmes, participating in projects funded by the Seventh Framework Program (FP7, 2017-2013) and by the Horizon 2020 calls. During the last period of H2020 (2014-2020), IDIVAL has obtained funding for the TIMELY project (A patient-centered early risk prediction, prevention, and intervention platform to support the continuum of care in coronary artery disease (CAD) using eHealth and artificial intelligence), first of its type in our institution. In 2018 obtained one Interreg Sudoe grant as a Coordinator, called TichroN - Use of ICTs as a tool to improve the comprehensive care of children with chronic illnesses, and in 2019 its first Interreg Europe grant INTENCIVE - INnovation and Technology ENhancing Customer OrIented Health SerVicEs. In 2019, IDIVAL obtained its first MSCA Grant - HELICAL. Moreover in 2019-2020 it has obtained three grants of an IMI2 project: EDHEN - European Health Data Evidence Network + additional call for COVID-19 and PRECISEADS - Molecular reclassification to find clinically useful biomarkers for systemic autoimmune diseases. Regarding Erasmus+ calls, IDIVAL has an extensive experience, two of the last ongoing projects under this umbrella are ALADDIN - Development of a Specific Training on Additive Manufacturing Technologies for Hospitals and PSYCH UP - Improving support for people affected by psychological disorders during their training path. Concerning the Third EU Health Programme IDIVAL has obtained funding from two Joint Actions (JADECARE and Chrodis+). Finally, IDIVAL is part of different European Infraestructures as EATRIS and ECRIN, and has received the recognition as a Reference Site by the European Innovation Partnership. The European Commission has also recognized the institution with the “HR Excellence in Research Award”, showing its commitment to improve its Human Resources policies in line with the European Charter for Researchers and the Code of Conduct of the Recruitment of Researchers (available information on our HRS4R website. Finally IDIVAL has a strong track record in assisting international consortia in proposal preparation, contract negotiation, project implementation and communication, IDIVAL’s European Projects Office personnel offers professional support along the whole life cycle of an EU project. The Transfer Technology & Valorization and Innovation Offices manage IPRs and licensing matters arising from projects. Last, the Office for Transfer of Research Results assists in developing and exploitation of business strategies, as well as in identifying results with a potential to be translated into products for the benefit of the society. For more information please visit our website.

Destination 1 – Staying healthy in a rapidly changing society

• HORIZON-HLTH-STAYHLTH-2021-01-01 Prevention of obesity through the life course
• HORIZON-HLTH-STAYHLTH-2021-01-02 HORIZON-HLTH-STAYHLTH-2021-01-02
• HORIZON-HLTH-STAYHLTH-2021-01-03 Supporting digital empowerment and health literacy
• HORIZON-HLTH-STAYHLTH-2021-01-04 A roadmap for personalised prevention

Destination 5. Unlocking the full potential of new tools, technologies and digital solutions for a healthy society

• HORIZON-HLTH-TOOL-2021-06 Smart medical devices and their surgical implantation for use in resource-constrained settings
• HORIZON-HLTH-TOOL-2021-06-02 Next generation advanced therapies to treat prevalent and high burden diseases with unmet needs
• HORIZON-HLTH-TOOL-2021-06-03 Innovative tools for use and re-use of health data (in particular electronic health records and/or patient registries)

Scope: You should apply to this call if you are looking for support from EIC Pathfinder Open to realise an ambitious vision for radically new technology, with potential to create new markets and/or to address global challenges. EIC Pathfinder Open supports early stage development of such future technologies (e.g. various activities at low Technology Readiness Levels 1-4), based on high-risk/high-gain science-towards-technology breakthrough research (including ‘deep-tech’). This research must provide the foundations of the technology you are envisioning. EIC Pathfinder Open may support your work, especially if it is highly risky: you may set out to try things that will not work; you may be faced with questions that nobody knows the answer to yet; you may realise that there are many aspects of the problem that you do not master. On the contrary, if the path you want to follow is incremental by nature or known, EIC Pathfinder Open will not support you. Before applying you should verify that your proposal meets all the following essential characteristics (‘Gatekeepers’):

• Convincing long-term vision of a radically new technology that has the potential to have a transformative positive effect to our economy and society.
• Concrete, novel and ambitious science-towards-technology breakthrough, providing advancement towards the envisioned technology.
• High-risk/high-gain research approach and methodology, with concrete and plausible objectives.

For more details, see the EIC Work Programme 2021.

19/05/2021

27/10/2021

22/06/2021-21/09/2021

22/06/2021-21/09/2021

22/06/2021-21/09/2021

22/06/2021-21/09/2021

22/06/2021-21/09/2021

22/06/2021-21/09/2021

TRANSCAN-3

Despite advances in immunotherapies, obstacles and challenges, including limited response rates, the inability to predict clinical efficacy, and potential side effects such as autoimmune reactions or cytokine release syndromes, remain and hinder further applications of immunotherapies in clinics. Thus, a deeper understanding of the TME, able to dissect distinct classes and subclasses of it, is essential for deciphering new mechanisms of immunotherapies, defining new predictive biomarkers, and identifying novel therapeutic targets. In the context of translational research, this topic at the intersection of laboratory and clinical research in immuno-oncology will comprise two general aims: Aim 1: Identification and validation of TME subclasses and their contribution to the resistance mechanisms: Translational research using tumour samples collected from retrospective and/or prospective cohorts of patients. Aim 2: Targeting TME to improve efficacy of immunotherapy in human patients.

NEURON Cofund2

Call for Proposals for Transnational Research Projects on Neurodevelopmental Disorders: Maintenance, improvement, and restoration of human health are of fundamental importance and a worldwide priority. Neurological and mental disorders are major causes of morbidity and, measured in Disability Adjusted Life Years (DALYS), account for 413.1 million DALYs globally. In Europe, people suffering from these conditions amount to 380 million. This not only imposes a high societal but also a major economic burden to the European population, leading to costs of more than 800 billion euros per year. A wide range of brain disorders already manifests during development in early life.

Website

Contact

Partnering IDIVAL

MAY 21

JUN 21

JUL 21

AGO 21

SEP 21

OCT 21

NOV 21

DIC 21

ENE 22

FEB 22

MAR 22

ABR 22

2021-2022

Joint Call Calendar

ERA PerMed

The JTC2021 is constructed around three research areas: Translating Basic to Clinical Research, Data and Information and Communication Technology and Research towards Responsible Implementation in Healthcare. Each proposal MUST address the modules Clinical Research, Towards Application in Healthcare and ELSA. Inclusion of modules Pre-clinical Research and Health Economic Research is optional.

Full proposal submission

Pre-proposal submission

Open for proposal

Evaluation period

Questions?

IDIVAL is the Health Research Institute of Cantabria, was created as a place for biomedical research, knowledge generation and socioeconomic tractor for the region as a result of the relationship that has been maintained over the years between the Marqués de Valdecilla University Hospital (HUMV) and the University of Cantabria (UC). Since its constitution in 2010, on March 2015, IDIVAL it is an accredited institution by the Health Institute Carlos III (ISCIII), and re accredited on June 2020 for a 5 years period, meaning that the work performed at IDIVAL meets the highest standards of quality. In fact, MVUH is ranked 59 of Health Institutions in SCImago Institutions Rankings (SIR) -Q1 Societal rank- in 2021 ranking and 319 worldwide (SIR). UC is ranked 3rd in Spain in productivity – sum of research, teaching and innovation (U-Ranking, BBVA Foundation & Ivie, 2020). The close collaboration between IDIVAL, UC, MVUH and the Health System, is allowing IDIVAL to foster basic-clinical collaborations and a fast-growing and excellent research activity, specifically oriented to generate new knowledge helping to solve the medical problems of the population. The Institution is made up of more than 750 people (workers, researchers and administrative staff). The scientific structure of IDIVAL includes 32 research groups distributed according to three categories (22 consolidated groups, 6 associated groups and 5 emerging groups), that focus their activity on six areas: cancer; neurosciences; transplantation; infection and immunity; metabolism, aging and lifestyle habits; and transversal research. IDIVAL has acquired an international reputation due to the the excellence of its standards of biomedical research, with a cumulative scientific production of more than 2,500 papers published, exceeding 7,000 citations, with an average of 8.4 citations per paper and an H-index of 58. Works published by researchers of the Institute in 2020 have reached 162,000 cumulative citations in the international literature. The 2017-2021 research plan approved by the institution is in line with Horizon Europe and the regional plan RIS3 for strategic development. IDIVAL is also a highly competitive research institute in terms of research funding. In 2019, IDIVAL attracted more than 8.5 M€ to fund its R&D activities, from which 2.3 M€ (27.8%) in competitive calls and 2.2 M€ from Cantabria Government (26.3%). The cumulative amount of research funding between 2015 and 2019 was more than 35.75 M€ (69.3% from competitive calls). Considering EU Projects, IDIVAL has experience in international research projects and programmes, participating in projects funded by the Seventh Framework Program (FP7, 2017-2013) and by the Horizon 2020 calls. During the last period of H2020 (2014-2020), IDIVAL has obtained funding for the TIMELY project (A patient-centered early risk prediction, prevention, and intervention platform to support the continuum of care in coronary artery disease (CAD) using eHealth and artificial intelligence), first of its type in our institution. In 2018 obtained one Interreg Sudoe grant as a Coordinator, called TichroN - Use of ICTs as a tool to improve the comprehensive care of children with chronic illnesses, and in 2019 its first Interreg Europe grant INTENCIVE - INnovation and Technology ENhancing Customer OrIented Health SerVicEs. In 2019, IDIVAL obtained its first MSCA Grant - HELICAL. Moreover in 2019-2020 it has obtained three grants of an IMI2 project: EDHEN - European Health Data Evidence Network + additional call for COVID-19 and PRECISEADS - Molecular reclassification to find clinically useful biomarkers for systemic autoimmune diseases. Regarding Erasmus+ calls, IDIVAL has an extensive experience, two of the last ongoing projects under this umbrella are ALADDIN - Development of a Specific Training on Additive Manufacturing Technologies for Hospitals and PSYCH UP - Improving support for people affected by psychological disorders during their training path. Concerning the Third EU Health Programme IDIVAL has obtained funding from two Joint Actions (JADECARE and Chrodis+). Finally, IDIVAL is part of different European Infraestructures as EATRIS and ECRIN, and has received the recognition as a Reference Site by the European Innovation Partnership. The European Commission has also recognized the institution with the “HR Excellence in Research Award”, showing its commitment to improve its Human Resources policies in line with the European Charter for Researchers and the Code of Conduct of the Recruitment of Researchers (available information on our HRS4R website. Finally IDIVAL has a strong track record in assisting international consortia in proposal preparation, contract negotiation, project implementation and communication, IDIVAL’s European Projects Office personnel offers professional support along the whole life cycle of an EU project. The Transfer Technology & Valorization and Innovation Offices manage IPRs and licensing matters arising from projects. Last, the Office for Transfer of Research Results assists in developing and exploitation of business strategies, as well as in identifying results with a potential to be translated into products for the benefit of the society. For more information please visit our website.

17/06/2021

07/09/2021

30/06/2021

31/12/2021

29/06/2021

20/12/2021

30/05/2021

Advanced Grant '21

Applicants for the ERC Advanced Grants - called Principal Investigators (PI) - are expected to be active researchers who have a track-record of significant research achievements in the last 10 years. The Principal Investigators should be exceptional leaders in terms of originality and significance of their research contributions. No specific eligibility criteria with respect to the academic requirements are foreseen.

Consolidator Grant

Researchers of any nationality with 7-12 years of experience since completion of PhD (Extensions are possible under certain circumstances — see the latest ERC Work Programme), a scientific track record showing great promise and an excellent research proposal.

Website

Contact

Partnering IDIVAL

ENE

FEB

MAR

ABR

MAY

JUN

JUL

AGO

SEP

OCT

NOV

DIC

European Research Council

Starting Grant '21/22

Researchers of any nationality with 2-7 years of experience since completion of PhD (Extensions are possible under certain circumstances — see the latest ERC Work Programme), a scientific track record showing great promise and an excellent research proposal

Proof of Concept '21

All Principal Investigators in an ERC frontier research project, that is either on going or has ended less than 12 months before 1 January 2020, are eligible to participate and apply for an ERC Proof of Concept Grant. The Principal Investigator must be able to demonstrate the relation between the idea to be taken to proof of concept and the ERC frontier research project (Starting, Consolidator, Advanced or Synergy) in question.

Synergy Grant '22

A group of two to maximum four Principal Investigators (PIs) – of which one will be designated as the corresponding PI (cPI) – working together and bringing different skills and resources to tackle ambitious research problems. No specific eligibility criteria regarding the academic training are foreseen for ERC Synergy Grants. PIs must present an early achievement track-record or a ten-year track-record, whichever is most appropriate. Proposals will be evaluated on the sole criterion of scientific excellence which, in the case the ERC Synergy Grants, takes on the additional meaning of outstanding intrinsic synergetic effect.

2021

First evaluation period

Proposal submission

Step 2 Interviews

Evaluation period 2

25/02/2021-08/04/2021

Questions?

IDIVAL is the Health Research Institute of Cantabria, was created as a place for biomedical research, knowledge generation and socioeconomic tractor for the region as a result of the relationship that has been maintained over the years between the Marqués de Valdecilla University Hospital (HUMV) and the University of Cantabria (UC). Since its constitution in 2010, on March 2015, IDIVAL it is an accredited institution by the Health Institute Carlos III (ISCIII), and re accredited on June 2020 for a 5 years period, meaning that the work performed at IDIVAL meets the highest standards of quality. In fact, MVUH is ranked 59 of Health Institutions in SCImago Institutions Rankings (SIR) -Q1 Societal rank- in 2021 ranking and 319 worldwide (SIR). UC is ranked 3rd in Spain in productivity – sum of research, teaching and innovation (U-Ranking, BBVA Foundation & Ivie, 2020). The close collaboration between IDIVAL, UC, MVUH and the Health System, is allowing IDIVAL to foster basic-clinical collaborations and a fast-growing and excellent research activity, specifically oriented to generate new knowledge helping to solve the medical problems of the population. The Institution is made up of more than 750 people (workers, researchers and administrative staff). The scientific structure of IDIVAL includes 32 research groups distributed according to three categories (22 consolidated groups, 6 associated groups and 5 emerging groups), that focus their activity on six areas: cancer; neurosciences; transplantation; infection and immunity; metabolism, aging and lifestyle habits; and transversal research. IDIVAL has acquired an international reputation due to the the excellence of its standards of biomedical research, with a cumulative scientific production of more than 2,500 papers published, exceeding 7,000 citations, with an average of 8.4 citations per paper and an H-index of 58. Works published by researchers of the Institute in 2020 have reached 162,000 cumulative citations in the international literature. The 2017-2021 research plan approved by the institution is in line with Horizon Europe and the regional plan RIS3 for strategic development. IDIVAL is also a highly competitive research institute in terms of research funding. In 2019, IDIVAL attracted more than 8.5 M€ to fund its R&D activities, from which 2.3 M€ (27.8%) in competitive calls and 2.2 M€ from Cantabria Government (26.3%). The cumulative amount of research funding between 2015 and 2019 was more than 35.75 M€ (69.3% from competitive calls). Considering EU Projects, IDIVAL has experience in international research projects and programmes, participating in projects funded by the Seventh Framework Program (FP7, 2017-2013) and by the Horizon 2020 calls. During the last period of H2020 (2014-2020), IDIVAL has obtained funding for the TIMELY project (A patient-centered early risk prediction, prevention, and intervention platform to support the continuum of care in coronary artery disease (CAD) using eHealth and artificial intelligence), first of its type in our institution. In 2018 obtained one Interreg Sudoe grant as a Coordinator, called TichroN - Use of ICTs as a tool to improve the comprehensive care of children with chronic illnesses, and in 2019 its first Interreg Europe grant INTENCIVE - INnovation and Technology ENhancing Customer OrIented Health SerVicEs. In 2019, IDIVAL obtained its first MSCA Grant - HELICAL. Moreover in 2019-2020 it has obtained three grants of an IMI2 project: EDHEN - European Health Data Evidence Network + additional call for COVID-19 and PRECISEADS - Molecular reclassification to find clinically useful biomarkers for systemic autoimmune diseases. Regarding Erasmus+ calls, IDIVAL has an extensive experience, two of the last ongoing projects under this umbrella are ALADDIN - Development of a Specific Training on Additive Manufacturing Technologies for Hospitals and PSYCH UP - Improving support for people affected by psychological disorders during their training path. Concerning the Third EU Health Programme IDIVAL has obtained funding from two Joint Actions (JADECARE and Chrodis+). Finally, IDIVAL is part of different European Infraestructures as EATRIS and ECRIN, and has received the recognition as a Reference Site by the European Innovation Partnership. The European Commission has also recognized the institution with the “HR Excellence in Research Award”, showing its commitment to improve its Human Resources policies in line with the European Charter for Researchers and the Code of Conduct of the Recruitment of Researchers (available information on our HRS4R website. Finally IDIVAL has a strong track record in assisting international consortia in proposal preparation, contract negotiation, project implementation and communication, IDIVAL’s European Projects Office personnel offers professional support along the whole life cycle of an EU project. The Transfer Technology & Valorization and Innovation Offices manage IPRs and licensing matters arising from projects. Last, the Office for Transfer of Research Results assists in developing and exploitation of business strategies, as well as in identifying results with a potential to be translated into products for the benefit of the society. For more information please visit our website.

11/03/2021-20/04/2021

Step 2 Interviews: end January 2022 Results of Step 2: end March 2022

20/05/2021-31/08/2021

15/07/2021-10/11/2021

15/07/2021-14/10/2021

Not published

16/11/2021 to 3 cut-off dates or closures:

• 15/02/2022
• 19/05/2022
• 29/09/2022

23/09/2021-13/01/2022

Not published

Not published

Advanced Grant '22

Applicants for the ERC Advanced Grants - called Principal Investigators (PI) - are expected to be active researchers who have a track-record of significant research achievements in the last 10 years. The Principal Investigators should be exceptional leaders in terms of originality and significance of their research contributions. No specific eligibility criteria with respect to the academic requirements are foreseen.

Consolidator Grant '22

Researchers of any nationality with 7-12 years of experience since completion of PhD (Extensions are possible under certain circumstances — see the latest ERC Work Programme), a scientific track record showing great promise and an excellent research proposal.

Website

Contact

Partnering IDIVAL

ENE

FEB

MAR

ABR

MAY

JUN

JUL

AGO

SEP

OCT

NOV

DIC

European Research Council

Starting Grant '22

Researchers of any nationality with 2-7 years of experience since completion of PhD (Extensions are possible under certain circumstances — see the latest ERC Work Programme), a scientific track record showing great promise and an excellent research proposal

Proof of Concept '22

All Principal Investigators in an ERC frontier research project, that is either on going or has ended less than 12 months before 1 January 2020, are eligible to participate and apply for an ERC Proof of Concept Grant. The Principal Investigator must be able to demonstrate the relation between the idea to be taken to proof of concept and the ERC frontier research project (Starting, Consolidator, Advanced or Synergy) in question.

Synergy Grant '22

A group of two to maximum four Principal Investigators (PIs) – of which one will be designated as the corresponding PI (cPI) – working together and bringing different skills and resources to tackle ambitious research problems. No specific eligibility criteria regarding the academic training are foreseen for ERC Synergy Grants. PIs must present an early achievement track-record or a ten-year track-record, whichever is most appropriate. Proposals will be evaluated on the sole criterion of scientific excellence which, in the case the ERC Synergy Grants, takes on the additional meaning of outstanding intrinsic synergetic effect.

2022

First evaluation period

Proposal submission

Step 2 Interviews

Evaluation period 2

23/09/2021-13/01/2022

Questions?

IDIVAL is the Health Research Institute of Cantabria, was created as a place for biomedical research, knowledge generation and socioeconomic tractor for the region as a result of the relationship that has been maintained over the years between the Marqués de Valdecilla University Hospital (HUMV) and the University of Cantabria (UC). Since its constitution in 2010, on March 2015, IDIVAL it is an accredited institution by the Health Institute Carlos III (ISCIII), and re accredited on June 2020 for a 5 years period, meaning that the work performed at IDIVAL meets the highest standards of quality. In fact, MVUH is ranked 59 of Health Institutions in SCImago Institutions Rankings (SIR) -Q1 Societal rank- in 2021 ranking and 319 worldwide (SIR). UC is ranked 3rd in Spain in productivity – sum of research, teaching and innovation (U-Ranking, BBVA Foundation & Ivie, 2020). The close collaboration between IDIVAL, UC, MVUH and the Health System, is allowing IDIVAL to foster basic-clinical collaborations and a fast-growing and excellent research activity, specifically oriented to generate new knowledge helping to solve the medical problems of the population. The Institution is made up of more than 750 people (workers, researchers and administrative staff). The scientific structure of IDIVAL includes 32 research groups distributed according to three categories (22 consolidated groups, 6 associated groups and 5 emerging groups), that focus their activity on six areas: cancer; neurosciences; transplantation; infection and immunity; metabolism, aging and lifestyle habits; and transversal research. IDIVAL has acquired an international reputation due to the the excellence of its standards of biomedical research, with a cumulative scientific production of more than 2,500 papers published, exceeding 7,000 citations, with an average of 8.4 citations per paper and an H-index of 58. Works published by researchers of the Institute in 2020 have reached 162,000 cumulative citations in the international literature. The 2017-2021 research plan approved by the institution is in line with Horizon Europe and the regional plan RIS3 for strategic development. IDIVAL is also a highly competitive research institute in terms of research funding. In 2019, IDIVAL attracted more than 8.5 M€ to fund its R&D activities, from which 2.3 M€ (27.8%) in competitive calls and 2.2 M€ from Cantabria Government (26.3%). The cumulative amount of research funding between 2015 and 2019 was more than 35.75 M€ (69.3% from competitive calls). Considering EU Projects, IDIVAL has experience in international research projects and programmes, participating in projects funded by the Seventh Framework Program (FP7, 2017-2013) and by the Horizon 2020 calls. During the last period of H2020 (2014-2020), IDIVAL has obtained funding for the TIMELY project (A patient-centered early risk prediction, prevention, and intervention platform to support the continuum of care in coronary artery disease (CAD) using eHealth and artificial intelligence), first of its type in our institution. In 2018 obtained one Interreg Sudoe grant as a Coordinator, called TichroN - Use of ICTs as a tool to improve the comprehensive care of children with chronic illnesses, and in 2019 its first Interreg Europe grant INTENCIVE - INnovation and Technology ENhancing Customer OrIented Health SerVicEs. In 2019, IDIVAL obtained its first MSCA Grant - HELICAL. Moreover in 2019-2020 it has obtained three grants of an IMI2 project: EDHEN - European Health Data Evidence Network + additional call for COVID-19 and PRECISEADS - Molecular reclassification to find clinically useful biomarkers for systemic autoimmune diseases. Regarding Erasmus+ calls, IDIVAL has an extensive experience, two of the last ongoing projects under this umbrella are ALADDIN - Development of a Specific Training on Additive Manufacturing Technologies for Hospitals and PSYCH UP - Improving support for people affected by psychological disorders during their training path. Concerning the Third EU Health Programme IDIVAL has obtained funding from two Joint Actions (JADECARE and Chrodis+). Finally, IDIVAL is part of different European Infraestructures as EATRIS and ECRIN, and has received the recognition as a Reference Site by the European Innovation Partnership. The European Commission has also recognized the institution with the “HR Excellence in Research Award”, showing its commitment to improve its Human Resources policies in line with the European Charter for Researchers and the Code of Conduct of the Recruitment of Researchers (available information on our HRS4R website. Finally IDIVAL has a strong track record in assisting international consortia in proposal preparation, contract negotiation, project implementation and communication, IDIVAL’s European Projects Office personnel offers professional support along the whole life cycle of an EU project. The Transfer Technology & Valorization and Innovation Offices manage IPRs and licensing matters arising from projects. Last, the Office for Transfer of Research Results assists in developing and exploitation of business strategies, as well as in identifying results with a potential to be translated into products for the benefit of the society. For more information please visit our website.

19/10/2021-17/03/2022

Not published

20/01/2022-28/04/2022

Not published

Not published

Not published

Not published

16/11/2021 to 3 cut-off dates or closures:

• 15/02/2022

16/11/2021 to 3 cut-off dates or closures:

• 19/05/2022

16/11/2021 to 3 cut-off dates or closures:

• 29/09/2022

Postdoctoral Fellows

• Continue supporting postdoctoral research and careers; open to researchers of any nationality
• New mind-sets and approaches to research and innovation throught interdisciplinary, inter-sectoral and international experience

Doctoral Networks

1 single action to implement doctoral programmes, including joint and industrial degrees (focus on career development plan, supervision, training: research and transferable skills)

• Industrial Doctorates
  • Training in academia and industry
  • Joint supervision
• Joint Doctorates
  • Joint collaborations leading to a joint/multiple doctoral degree
  • Joint selection and supervision

Website

Contact

Partnering IDIVAL

ENE

FEB

MAR

ABR

MAY

JUN

JUL

AGO

SEP

OCT

NOV

DIC

Other Actions

COST

Participants are invited to submit COST Action proposals contributing to the scientific, technological, economic, cultural or societal knowledge advancement and development of Europe. Multi- and interdisciplinary proposals are encouraged. The Open Call Action proposal submission, evaluation, selection and approval (SESA) procedure is fully science and technology-driven and will ensure a simple, transparent and competitive proposal evaluation and selection process, reflecting the bottom-up, open and inclusive principles of COST. Participants planning to submit a proposal for a COST Action will need to refer to the SESA guidelines and to the Open Call Announcement on the Documents and Guidelines page. For any questions related to the open call and how to get funding, please contact opencall@cost.eu

MSCA & Citizens

Aims to bring research and researchers closer to the public at large, to increase awareness of research and innovation activities and to boost public recognition of science and research education. Who applies? Organisations in EU Member States and Horizon Europe Associated Countries.

COFUND

Los programas Marie Skłodowska Curie Actions-COFUND (MSCA-COFUND) de la Comisión Europea ofrecen financiación adicional para programas de investigación que ofrecen una dimensión internacional e intersectorial a la formación y a la carrera investigadora. Este documento recopila información clave (tipo de candidatos, área de investigación, duración del contrato y salarios de la convocatoria) para los investigadores que quieran concurrir a alguna de las convocatorias abiertas en 2019 y 2020 de programas MSCA-COFUND en diferentes instituciones en España.

2021-2022

Proposal submission

2021

2022

MSCA

Postdoctoral Fellows

• Continue supporting postdoctoral research and careers; open to researchers of any nationality
• New mind-sets and approaches to research and innovation throught interdisciplinary, inter-sectoral and international experience

Doctoral Networks

1 single action to implement doctoral programmes, including joint and industrial degrees (focus on career development plan, supervision, training: research and transferable skills)

• Industrial Doctorates
  • Training in academia and industry
  • Joint supervision
• Joint Doctorates
  • Joint collaborations leading to a joint/multiple doctoral degree
  • Joint selection and supervision

COFUND

Los programas Marie Skłodowska Curie Actions-COFUND (MSCA-COFUND) de la Comisión Europea ofrecen financiación adicional para programas de investigación que ofrecen una dimensión internacional e intersectorial a la formación y a la carrera investigadora. Este documento recopila información clave (tipo de candidatos, área de investigación, duración del contrato y salarios de la convocatoria) para los investigadores que quieran concurrir a alguna de las convocatorias abiertas en 2019 y 2020 de programas MSCA-COFUND en diferentes instituciones en España.

2021

2021

2021

2021-2022

2021

2022

2022

2022-2023

29/10/2021 12:00 CET

Questions?

IDIVAL is the Health Research Institute of Cantabria, was created as a place for biomedical research, knowledge generation and socioeconomic tractor for the region as a result of the relationship that has been maintained over the years between the Marqués de Valdecilla University Hospital (HUMV) and the University of Cantabria (UC). Since its constitution in 2010, on March 2015, IDIVAL it is an accredited institution by the Health Institute Carlos III (ISCIII), and re accredited on June 2020 for a 5 years period, meaning that the work performed at IDIVAL meets the highest standards of quality. In fact, MVUH is ranked 59 of Health Institutions in SCImago Institutions Rankings (SIR) -Q1 Societal rank- in 2021 ranking and 319 worldwide (SIR). UC is ranked 3rd in Spain in productivity – sum of research, teaching and innovation (U-Ranking, BBVA Foundation & Ivie, 2020). The close collaboration between IDIVAL, UC, MVUH and the Health System, is allowing IDIVAL to foster basic-clinical collaborations and a fast-growing and excellent research activity, specifically oriented to generate new knowledge helping to solve the medical problems of the population. The Institution is made up of more than 750 people (workers, researchers and administrative staff). The scientific structure of IDIVAL includes 32 research groups distributed according to three categories (22 consolidated groups, 6 associated groups and 5 emerging groups), that focus their activity on six areas: cancer; neurosciences; transplantation; infection and immunity; metabolism, aging and lifestyle habits; and transversal research. IDIVAL has acquired an international reputation due to the the excellence of its standards of biomedical research, with a cumulative scientific production of more than 2,500 papers published, exceeding 7,000 citations, with an average of 8.4 citations per paper and an H-index of 58. Works published by researchers of the Institute in 2020 have reached 162,000 cumulative citations in the international literature. The 2017-2021 research plan approved by the institution is in line with Horizon Europe and the regional plan RIS3 for strategic development. IDIVAL is also a highly competitive research institute in terms of research funding. In 2019, IDIVAL attracted more than 8.5 M€ to fund its R&D activities, from which 2.3 M€ (27.8%) in competitive calls and 2.2 M€ from Cantabria Government (26.3%). The cumulative amount of research funding between 2015 and 2019 was more than 35.75 M€ (69.3% from competitive calls). Considering EU Projects, IDIVAL has experience in international research projects and programmes, participating in projects funded by the Seventh Framework Program (FP7, 2017-2013) and by the Horizon 2020 calls. During the last period of H2020 (2014-2020), IDIVAL has obtained funding for the TIMELY project (A patient-centered early risk prediction, prevention, and intervention platform to support the continuum of care in coronary artery disease (CAD) using eHealth and artificial intelligence), first of its type in our institution. In 2018 obtained one Interreg Sudoe grant as a Coordinator, called TichroN - Use of ICTs as a tool to improve the comprehensive care of children with chronic illnesses, and in 2019 its first Interreg Europe grant INTENCIVE - INnovation and Technology ENhancing Customer OrIented Health SerVicEs. In 2019, IDIVAL obtained its first MSCA Grant - HELICAL. Moreover in 2019-2020 it has obtained three grants of an IMI2 project: EDHEN - European Health Data Evidence Network + additional call for COVID-19 and PRECISEADS - Molecular reclassification to find clinically useful biomarkers for systemic autoimmune diseases. Regarding Erasmus+ calls, IDIVAL has an extensive experience, two of the last ongoing projects under this umbrella are ALADDIN - Development of a Specific Training on Additive Manufacturing Technologies for Hospitals and PSYCH UP - Improving support for people affected by psychological disorders during their training path. Concerning the Third EU Health Programme IDIVAL has obtained funding from two Joint Actions (JADECARE and Chrodis+). Finally, IDIVAL is part of different European Infraestructures as EATRIS and ECRIN, and has received the recognition as a Reference Site by the European Innovation Partnership. The European Commission has also recognized the institution with the “HR Excellence in Research Award”, showing its commitment to improve its Human Resources policies in line with the European Charter for Researchers and the Code of Conduct of the Recruitment of Researchers (available information on our HRS4R website. Finally IDIVAL has a strong track record in assisting international consortia in proposal preparation, contract negotiation, project implementation and communication, IDIVAL’s European Projects Office personnel offers professional support along the whole life cycle of an EU project. The Transfer Technology & Valorization and Innovation Offices manage IPRs and licensing matters arising from projects. Last, the Office for Transfer of Research Results assists in developing and exploitation of business strategies, as well as in identifying results with a potential to be translated into products for the benefit of the society. For more information please visit our website.

MSCA-DN: 22/06/2021-16/11/2021

03/05/22-15/11/2022

MSCA-PF: 22/06/2021-12/10/2021

12/10/2021-10/02/2022

17/06/2021-07/10/2021

14/04/2022-14/09/2022

11/10/2022-03/02/2023

Website

Contact

Partnering IDIVAL

2021-2022

Interreg Europe

Estimated calendar

ENE

FEB

MAR

ABR

MAY

JUN

JUL

AGO

SEP

OCT

NOV

DIC

Interreg Europe is in the process of preparing the new programme for interregional cooperation. The provisional timeline presents the key steps in the process.

Questions?

IDIVAL is the Health Research Institute of Cantabria, was created as a place for biomedical research, knowledge generation and socioeconomic tractor for the region as a result of the relationship that has been maintained over the years between the Marqués de Valdecilla University Hospital (HUMV) and the University of Cantabria (UC). Since its constitution in 2010, on March 2015, IDIVAL it is an accredited institution by the Health Institute Carlos III (ISCIII), and re accredited on June 2020 for a 5 years period, meaning that the work performed at IDIVAL meets the highest standards of quality. In fact, MVUH is ranked 59 of Health Institutions in SCImago Institutions Rankings (SIR) -Q1 Societal rank- in 2021 ranking and 319 worldwide (SIR). UC is ranked 3rd in Spain in productivity – sum of research, teaching and innovation (U-Ranking, BBVA Foundation & Ivie, 2020). The close collaboration between IDIVAL, UC, MVUH and the Health System, is allowing IDIVAL to foster basic-clinical collaborations and a fast-growing and excellent research activity, specifically oriented to generate new knowledge helping to solve the medical problems of the population. The Institution is made up of more than 750 people (workers, researchers and administrative staff). The scientific structure of IDIVAL includes 32 research groups distributed according to three categories (22 consolidated groups, 6 associated groups and 5 emerging groups), that focus their activity on six areas: cancer; neurosciences; transplantation; infection and immunity; metabolism, aging and lifestyle habits; and transversal research. IDIVAL has acquired an international reputation due to the the excellence of its standards of biomedical research, with a cumulative scientific production of more than 2,500 papers published, exceeding 7,000 citations, with an average of 8.4 citations per paper and an H-index of 58. Works published by researchers of the Institute in 2020 have reached 162,000 cumulative citations in the international literature. The 2017-2021 research plan approved by the institution is in line with Horizon Europe and the regional plan RIS3 for strategic development. IDIVAL is also a highly competitive research institute in terms of research funding. In 2019, IDIVAL attracted more than 8.5 M€ to fund its R&D activities, from which 2.3 M€ (27.8%) in competitive calls and 2.2 M€ from Cantabria Government (26.3%). The cumulative amount of research funding between 2015 and 2019 was more than 35.75 M€ (69.3% from competitive calls). Considering EU Projects, IDIVAL has experience in international research projects and programmes, participating in projects funded by the Seventh Framework Program (FP7, 2017-2013) and by the Horizon 2020 calls. During the last period of H2020 (2014-2020), IDIVAL has obtained funding for the TIMELY project (A patient-centered early risk prediction, prevention, and intervention platform to support the continuum of care in coronary artery disease (CAD) using eHealth and artificial intelligence), first of its type in our institution. In 2018 obtained one Interreg Sudoe grant as a Coordinator, called TichroN - Use of ICTs as a tool to improve the comprehensive care of children with chronic illnesses, and in 2019 its first Interreg Europe grant INTENCIVE - INnovation and Technology ENhancing Customer OrIented Health SerVicEs. In 2019, IDIVAL obtained its first MSCA Grant - HELICAL. Moreover in 2019-2020 it has obtained three grants of an IMI2 project: EDHEN - European Health Data Evidence Network + additional call for COVID-19 and PRECISEADS - Molecular reclassification to find clinically useful biomarkers for systemic autoimmune diseases. Regarding Erasmus+ calls, IDIVAL has an extensive experience, two of the last ongoing projects under this umbrella are ALADDIN - Development of a Specific Training on Additive Manufacturing Technologies for Hospitals and PSYCH UP - Improving support for people affected by psychological disorders during their training path. Concerning the Third EU Health Programme IDIVAL has obtained funding from two Joint Actions (JADECARE and Chrodis+). Finally, IDIVAL is part of different European Infraestructures as EATRIS and ECRIN, and has received the recognition as a Reference Site by the European Innovation Partnership. The European Commission has also recognized the institution with the “HR Excellence in Research Award”, showing its commitment to improve its Human Resources policies in line with the European Charter for Researchers and the Code of Conduct of the Recruitment of Researchers (available information on our HRS4R website. Finally IDIVAL has a strong track record in assisting international consortia in proposal preparation, contract negotiation, project implementation and communication, IDIVAL’s European Projects Office personnel offers professional support along the whole life cycle of an EU project. The Transfer Technology & Valorization and Innovation Offices manage IPRs and licensing matters arising from projects. Last, the Office for Transfer of Research Results assists in developing and exploitation of business strategies, as well as in identifying results with a potential to be translated into products for the benefit of the society. For more information please visit our website.